CION Ameerpet
The first question
Proving the cancer started in the ovary
This is the step that matters most and the one most often rushed. A mucinous tumour that reached the ovary from the bowel, appendix or stomach is a different disease with different treatment — and it can look identical to a true ovarian primary on the operating table.
Size and sidedness — the first sort
Pathologists start with two crude but useful facts: how big the tumour is, and whether both ovaries are involved. A single large mucinous tumour in one ovary, with a smooth outer surface, usually turns out to be a genuine ovarian primary. Tumours in both ovaries, or smaller tumours with deposits on the ovarian surface, are far more often secondary.
This is a starting point, not a conclusion. Some appendiceal and colonic cancers produce a large one-sided ovarian mass that fits the “primary” description perfectly, and some genuine ovarian primaries are small. The rule sorts the pile; the rest of the work-up decides individual cases.
Immunohistochemistry — the protein fingerprint
The tumour tissue is stained for a panel of proteins that differ between organs. A primary ovarian mucinous carcinoma is usually CK7-positive with patchy or absent CK20, and often expresses PAX8. A metastasis from the lower gastrointestinal tract typically shows the reverse pattern — CK7-negative, with CK20, CDX2 and SATB2 positive.
The panel is powerful but not perfect. Tumours from the stomach, pancreas and biliary tract overlap heavily with the ovarian pattern, and a minority of ovarian primaries stain atypically. This is why a good pathology report reads as a considered opinion drawing on the stains, the imaging and the surgical findings together, rather than a single positive line.
The appendix, every time
The appendix is inspected during surgery for a mucinous ovarian tumour and removed if it looks abnormal. An appendiceal mucinous neoplasm can seed both ovaries and the peritoneal cavity while remaining small and silent in itself, and it is one of the commonest sources of a mucinous tumour mistaken for ovarian cancer.
If gelatinous mucin is found spread through the abdomen — the picture called pseudomyxoma peritonei — the appendix is almost always the origin, not the ovary. That distinction changes the surgical plan, the chemotherapy and the specialists involved, so it is established before treatment rather than after.
Looking at the bowel and the stomach
A colonoscopy and, where the picture warrants it, an upper gastrointestinal endoscopy are part of a proper mucinous work-up. Women often find this puzzling — the cancer is in the ovary, so why examine the gut? The answer is that a small bowel or stomach cancer can be invisible on a CT scan while having already deposited a large tumour in the ovary.
A CT scan of the abdomen and pelvis is done alongside, to look at the appendix, the pancreas and the peritoneum. Where these are all clear and the pathology fits, the diagnosis of a primary ovarian mucinous carcinoma stands on solid ground rather than on assumption.
Tumour markers that are not CA-125
CA-125 is the marker most women have heard of, and in mucinous disease it is frequently normal even when a substantial tumour is present. Relying on it here produces false reassurance. CEA and CA 19-9 are raised more often in mucinous tumours and are the more useful pair to check.
A markedly raised CEA with a normal CA-125 shifts suspicion towards a gastrointestinal origin and usually prompts endoscopy. No marker decides anything by itself. Their real value comes later: whichever marker was raised at diagnosis becomes the one worth following during and after treatment.
What changes if it turns out to be gastrointestinal
Everything downstream. A mucinous cancer that started in the colon, appendix or stomach is staged, treated and followed as a cancer of that organ. The chemotherapy is different, the surgery is different, the specialists are different, and the outlook is judged against a different set of figures.
This is precisely why the question is settled before treatment begins rather than after a course of the wrong chemotherapy. If it emerges only later, the plan is rebuilt from the beginning — and months have been lost. Ask your team directly whether a gastrointestinal primary has been excluded, and what they excluded it with.
